πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

Phase II Pipeline Programs

Proof-of-concept and dose-finding clinical programs in Phase II development.

Programs
7,238

Quick answer

NovaPharmaNews tracks 7,238 phase ii pharmaceutical pipeline programs from ClinicalTrials.gov. Proof-of-concept and dose-finding clinical programs in Phase II development.

Top sponsors

Page 124 of 151

  1. TEV-53408, Placebo to match TEV-53408

    Lacuna Pharma Pty Ltd

    Celiac Disease

    phase 2 small molecule active

    1 trial

  2. TEV-56286

    Teva Pharma GmbH

    Multiple System Atrophy

    phase 2 small molecule active

    2 trials

  3. TG-0054

    Structure Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  4. TG-0054 (2.24 mg/kg)

    Structure Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  5. TG-0054 combined with G-CSF

    Structure Therapeutics

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial

  6. TG-873870 (Nemonoxacin)

    Biotech Pharmaceutical Co.,

    Diabetic Foot Infections

    phase 2 small molecule completed

    1 trial

  7. TGR-1202

    TG THERAPEUTICS, INC.

    Chronic Lymphocytic Leukemia

    phase 2 small molecule terminated

    1 trial

  8. TGR-1202

    TG THERAPEUTICS, INC.

    Follicular Lymphoma

    phase 2 small molecule terminated

    1 trial

  9. TGRX-326

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Non-small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  10. THC

    BRIGHT MINDS BIOSCIENCES INC.

    THC

    phase 2 small molecule active

    1 trial

  11. THOR-707

    Sanofi Pasteur

    Metastasis

    phase 2 small molecule terminated

    1 trial

  12. THOR-707

    Sanofi Pasteur

    Malignant Melanoma

    phase 2 small molecule terminated

    1 trial

  13. THYMOGLOBULINE 5 mg/ml, poudre pour solution pour perfusion

    The George Institute

    haematological malignancies

    phase 2 small molecule active

    1 trial

  14. TIMP-GLIA

    Takeda

    Celiac Disease

    phase 2 small molecule completed

    2 trials

  15. TIN816, Placebo to TIN816 70mg powder for solution for injection or infusion

    Novartis Pharmaceuticals

    Acute kidney injury

    phase 2 small molecule active

    1 trial

  16. TIN816, Sterile 0.9% sodium chloride solution for infusion will be administered as placebo to participants randomized to the placebo treatment. The solution is ready to use in a 100mL infusion bag of 0.9% sodium chloride solution

    Novartis Pharmaceuticals

    Sepsis associated acute kidney injury

    phase 2 small molecule active

    1 trial

  17. TIRZEPATIDE, TIRZEPATIDE, Placebo to match LY3298176, TIRZEPATIDE, IOHEXOL , TIRZEPATIDE, TIRZEPATIDE, TIRZEPATIDE

    Eli Lilly Co.

    Chronic Kidney Disease, CKD, Obesity, Overweight, T2D, Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  18. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    High-risk B-cell acute lymphoblastic leukemia

    phase 2 small molecule active

    1 trial

  19. TISAGENLECLEUCEL

    Novartis Pharmaceuticals

    Adult patients with refractory or relapsed follicular lymphoma

    phase 2 small molecule active

    1 trial

  20. TISLELIZUMAB

    Fondazione Telethon ETS

    Hodgkin lymphoma

    phase 2 small molecule active

    1 trial

  21. TKM-080301

    Arbutus Biopharma Corp

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  22. TKM-080301

    Arbutus Biopharma Corp

    Cancer

    phase 2 small molecule completed

    1 trial

  23. TL-895, TL-895

    Lacuna Pharma Pty Ltd

    B Cell Malignancies and Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    phase 2 small molecule active

    1 trial

  24. TL-895, TL-895, TL-895, TL-895 matching placebo, TL-895, TL-895

    Lacuna Pharma Pty Ltd

    Indolent Systemic Mastocytosis

    phase 2 small molecule active

    1 trial

  25. TMC207

    Janssen Cilag International NV

    Tuberculosis

    phase 2 small molecule completed

    1 trial

  26. TMC207

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  27. TMC207 (J)

    BRIGHT MINDS BIOSCIENCES INC.

    Pulmonary Tuberculosis

    phase 2 small molecule completed

    1 trial

  28. TMC435

    Elan Pharma International

    Hepatitis C

    phase 2 small molecule completed

    1 trial

  29. TN-201

    Tenaya Therapeutics

    Hypertrophic Cardiomyopathy

    phase 2 gene therapy active

    1 trial

  30. TNFΞ± Monoclonal Antibody

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Spinal Cord Injuries

    phase 2 small molecule active

    1 trial

  31. TNG260

    Tango Therapeutics

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  32. TNG348

    Tango Therapeutics

    Breast Cancer

    phase 2 small molecule terminated

    1 trial

  33. TNG456

    Tango Therapeutics

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  34. TNG462

    Revolution Medicines

    PDAC

    phase 2 small molecule active

    1 trial

  35. TNG462

    Tango Therapeutics

    Locally Advanced Solid Tumor

    phase 2 small molecule active

    1 trial

  36. TNG462, S095035 tablet 25mg, S095035 tablet 50mg, TNG462, TNG462

    The George Institute

    MTAP-deleted advanced or metastatic solid tumors

    phase 2 small molecule active

    1 trial

  37. TNG908

    Tango Therapeutics

    Locally Advanced Solid Tumor

    phase 2 small molecule terminated

    1 trial

  38. TNG908, TNG908, TNG908, TNG908, MIDAZOLAM

    Tango Therapeutics

    "Ph1: β€’Locally advanced (LA) or metastatic MTAP-deleted (met.MTAP-del.) solid tumors β€’MTAP-del.relapsed or refrac. Grade 4 astrocytoma or glioblastoma multiforme (R/R GBM) Ph2: A1:LA or met.MTAP-del. squamous and nonsquamous NSCLC A2:LA or met.MTAP-del. mesothelioma A3:LA or met.MTAP-del. sarcoma A4:LA or met.MTAP-del. pancreatic ductal adenocarcinoma or adenosquamous carcinoma w/predominantly adenocarcinoma histology A5:Other LA or met.MTAP-del. solid tumors A6:MTAP-del. R/R GBM"

    phase 2 small molecule active

    1 trial

  39. TNO155, JDQ443, TNO155, VDT482/ BGB-A317, JDQ443, TNO155, TNO155

    Novartis Pharmaceuticals

    Advance solid tumors harboring the KRAS G12C mutation

    phase 2 small molecule active

    1 trial

  40. TNTL capsule

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Accidental Exposure While Preparing Drug for Administration

    phase 2 small molecule completed

    1 trial

  41. TNX-102 SL

    Tonix Pharmaceuticals Holding

    Post-Acute Sequelae of SARS-CoV-2 (PASC) Infection

    phase 2 small molecule completed

    1 trial

  42. TNX-1300

    Tonix Pharmaceuticals Holding

    Cocaine Intoxication

    phase 2 small molecule terminated

    1 trial

  43. TNX-1300 (Injection)

    BRIGHT MINDS BIOSCIENCES INC.

    Cocaine Use

    phase 2 small molecule terminated

    1 trial

  44. TNX-1500

    Tonix Pharmaceuticals Holding

    Kidney Transplant

    phase 2 small molecule active

    1 trial

  45. TNX-1900

    Tonix Pharmaceuticals Holding

    Chronic Migraine

    phase 2 small molecule completed

    1 trial

  46. TNX-201

    Tonix Pharmaceuticals Holding

    Tension-Type Headache

    phase 2 small molecule completed

    1 trial

  47. TNX-601 ER

    Tonix Pharmaceuticals Holding

    Depression

    phase 2 small molecule completed

    1 trial

  48. TOCILIZUMAB , CYCLOPHOSPHAMIDE , CD19-CAR_Lenti, FLUDARABINE , LEVETIRACETAM

    Fondazione Telethon ETS

    Refractory Systemic Autoimmune Diseases

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many Phase II pipeline programs are in the directory?

7,238 published programs match this development stage in our ClinicalTrials.gov index.

What defines this pipeline stage?

Phase and status reflect ClinicalTrials.gov registry fields at last sync. See our clinical trial phases reference for methodology.

Data attribution: Data sources Β· All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates β€” weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.